MedPath

To Linguistically and Psychometrically Validate the Hong Kong Chinese Version of the BPH 3-item Questionnaire

Active, not recruiting
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Other: BPH 3-item questionnaire
Registration Number
NCT05785286
Lead Sponsor
Chinese University of Hong Kong
Brief Summary

This study is to linguistically and psychometrically validate the translated and culturally adapted Hong Kong Chinese version of the BPH 3-item questionnaire.

Detailed Description

A new BPH 3-item questionnaire has recently been developed and published, and it may serve as a screening tool for male-LUTS due to symptomatic BPE. The questionnaire consists of only three items. A raw score ranging from 0 to 5 is assigned to each of the items, giving a final total score varying from 0 (no symptom) to 15 (very symptomatic). This questionnaire has been translated and validated into five different European languages and was harmonized cross-culturally for linguistic validation, followed by psychometric accuracy testing.

This new questionnaire may help rationalize more early commencement of therapy aimed at reducing the prostate size for the treatment of male LUTS due to BPE.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
Male
Target Recruitment
66
Inclusion Criteria
  • 18 - 90 years old Chinese male subjects presented with male-LUTS for at least 4 weeks
  • The subjects are able to read and fully comprehend with the content of the questionnaires
  • The subjects are willing to give informed consent for the study
Read More
Exclusion Criteria
  • peak uroflow ≤4mL/sec;
  • post-void residual (PVR) ≥300 mL;
  • unable to give informed consent
  • need of clean intermittent self-catheterization / indwelling urethral catheterization at the time of enrolment;
  • Surgical treatment (e.g. TURP) of bladder outlet obstruction / symptomatic benign prostate enlargement (BPE) ≤ 3 months before entry into the study
  • clinical suspicion / presence of untreated urethral stricture and/or bladder neck stenosis,
  • clinical suspicion / presence of genitourinary cancer including active prostate cancer with ongoing surgical or radiation treatment, or the need of treatment, or bladder cancer, or persistent unexplained hematuria;
  • uncontrolled heart failure / diabetes mellitus(DM) / hypertension(HT);
  • neuropathic bladder;
  • Currently on dialysis or in consideration for dialysis due to end stage renal disease;
  • More than 3 urinary tract infections within the last 12 months;
  • Unstable dose of diuretic within the past 3 months;
  • Has an artificial urinary sphincter;
  • Impaired mental status;
  • male-LUTS due to urinary tract infections / chronic prostatitis / chronic pelvic pain
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Subject who is waiting for their transurethral ablative prostate surgeryBPH 3-item questionnaireMale subjects who are waiting for BPH surgery and are still able to pass urine on their own without the need of assistance or urethral catheterization.
Subject with male LUTSBPH 3-item questionnaireMale subjects who have been bothered by male LUTS for at least 4 weeks and are still able to pass urine on their own without the need of assistance or urethral catheterization.
Primary Outcome Measures
NameTimeMethod
Reliability of BPH 3-item questionnaireup to 24 weeks

Reliability was assessed by internal consistency and test-retest correlation. (ρ) correlation, with the IPSS (total score / voiding domain (ie Q.1, 3, 5, 6) and prostate volume measured by TRUS.

Internal consistency of BPH 3-item questionnaireup to 24 weeks

Internal consistency was assessed by Cronbach's alpha coefficients, with \>0.7 being considered acceptable

The convergent validity of the BPH 3-item questionnaireup to 24 weeks

was estimated by Spearman rho (ρ) correlation, with the IPSS (total score / voiding domain (ie Q.1, 3, 5, 6) and prostate volume measured by TRUS.

Test-retest reliability of BPH 3-item questionnaireup to 24 weeks

Test-retest reliability was assessed by intra-class correlation coefficient. Values between 0.6 and 0.8 indicate substantial agreement, and values over 0.8 indicate near-perfect agreement

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Prince of Wales Hospital

🇭🇰

Sha Tin, Hong Kong

Alice Ho Miu Ling Nethersole Hospital

🇭🇰

Hong Kong, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath